In conclusion, HSD17B13:TA mitigates the increased risk of liver fibrosis progression and HCC in HCV-infected patients with PNPLA3 I148M variant; further studies are required to better elucidate the underlying pathogenic mechanisms and to evaluate the potential clinical applications of this observation. Here, HSD17B13 is linked to Hepatic fibrosis.